Investment Worth $11 Million Secured by ADC Bio for Bioconjugation Facility

Construction of New Plant Investment Worth $11 Million Secured by ADC Bio for Bioconjugation Facility

29.09.2017Author / Editor: Ahlam Rais / Wolfgang Ernhofer

ADC Biotechnology plans to construct a facility at its new site in the UK. The plant is expected to support manufacturing in all clinical phases and small-scale commercial production of ADCs.

Related Vendors

AZO GmbH + Co. KG

Pörner Ingenieurgesellschaft mbH

Maag Pump Systems AG

The bioconjugation facility is scheduled to be operational by December 2018.
(Source: Deposit Photos)

Wales/UK – ADC Biotechnology (ADC Bio) has recently announced that it has secured investment for the construction of a $11 million bioconjugation facility at its new site in Deeside, North Wales, UK. The company is a specialist antibody drug conjugate (ADC) contract services company with proprietary conjugation technology that has been designed to overcome process and aggregation challenges during the development of new ADCs.

The 6,500 sq m facility is scheduled to be operational by December 2018 and is expected to support manufacturing in all clinical phases and small-scale commercial production of ADCs. The new integrated facility will enable ADC Bio to complement its long established technical services business that provides small scale R&D through to pre-clinical testing, with three on site laboratories and analytical testing capabilities.

The purpose-built, dual stream bioconjugation facility will provide a suite of capabilities ranging from R&D technical services, quality control, QA, warehousing, and process development through to manufacturing – all of which will occupy just 50% of the unit’s footprint. Consequently, ADC Bio will have free capacity to upscale quickly from early clinical phases into late phase and commercial manufacturing within the same footprint at the new facility.

Subsequent phases are planned for 2018 onwards and will add further capacity for large scale clinical and commercial, and potentially, dosage form production (fill/finish).

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:44921157)